Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 20, 2017
Issued Date -
N/A
app pub date -
Dec 21, 2012
filing date -
Dec 23, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully